|
FOR RELEASE ON |
21 November 2022 |
IP Group plc - Life sciences presentation postponed
Further to the announcement on 2 November, IP Group plc (LSE: IPO) ("IP Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, notes that due to circumstances beyond its control, the Company is postponing the investor presentation titled 'Life Sciences: Changing Medicine' that was scheduled for Wednesday 30 November 2022.
The Company apologises for any inconvenience this may cause and looks forward to rescheduling as soon as practicable.
For more information, please contact:
|
IP Group plc |
|
|
Liz Vaughan-Adams, Communications |
+44 (0) 20 7444 0050 |
|
Charlotte Street Partners |
|
|
David Gaffney |
+44 (0) 7854 609998 |
|
Andrew Wilson |
+44 (0) 7810 636995 |
Notes for editors
About IP Group
IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com.
ENDS
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
